• Profile
Close

DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction

BMC Nephrology Mar 08, 2019

Kim SJ, et al. - Researchers used a rat model of chronic kidney disease (CKD) and CKD with myocardial ischemia/reperfusion (MI/R) using male Sprague Dawley rats with 5/6 nephrectomy to determine the alterations in renal and myocardial GLP-1 receptor (GLP-1R) expression in CKD with MI/R. They induced myocardial ischemia by ligating left coronary artery, which was then released for 30 minutes 1 week after 5/6 nephrectomy. Once daily for 8 weeks dipeptidyl-peptidase 4 (DPP-4) inhibitors were administered orally with linagliptin. Using immunohistochemistry and western blot analysis, renal cortical and myocardial GLP-1R expression were assessed. In CKD, an enhanced DPP-4 activity was evident. Reduction in renal injury and an increase in myocardial GLP-1R expression were noted as the consequences of treatment with linagliptin in CKD with MI/R. Based on the findings, both cardio- and renoprotective effects could be achieved with activation of renal and myocardial GLP-1R expression.

Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay